Mumbai, April 16, 2018: Pharma Major, Alembic Pharma said that it has received USFDA approval for its Abbreviated New Drug Application (ANDA) Acyclovir ointment USP, 5 per cent.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Zovirax ointment 5 per cent, of Valeant Pharmaceuticals North America LLC. Acyclovir ointment USP 5 per cent, is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients.
Acyclovir, 5 per cent, have an estimated market size USD 145 million for twelve months ending December 2016 according to IMS. Alembic now has a total of 71 ANDA approvals (63 final approvals and 8 tentative approvals) from USFDA.
United News of India
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…